Home › Free Stock Grades › BMRN
BioMarin Pharmaceutical Inc. (BMRN) Stock Grade
BMRN · Healthcare
A
Market Cap
$13.0B
P/E Ratio
32.7
Revenue Growth (YoY)
+12.9%
Net Margin
10.8%
Return on Equity
5.7%
Dividend Yield
None
About BioMarin Pharmaceutical Inc.'s fundamentals
BioMarin Pharmaceutical is a $13.0 billion biotech company posting revenue growth of 12.9% year-over-year with a net profit margin of 10.8%, indicating profitable operations despite the capital-intensive nature of drug development. The company trades at a P/E ratio of 32.7, reflecting market expectations for a growth-stage biotech firm, though its return on equity of 5.7% suggests relatively modest returns on shareholder capital. The company does not currently pay a dividend, which is typical for biotech firms that prioritize reinvesting earnings into research and development.